Health Insurance Denial: How to Appeal

Print Friendly

Immunoglobulin (Ig) therapy is an expensive therapy. Unfortunately some insurance companies deny Ig therapy for primary immunodeficiency, until the insurer understands the rationale behind this expensive life sustaining therapy. They are very reluctant to approve expensive payments per year where indications are not substantiated.

Below are some “how to” tips from a clinical immunologist that has been successful in overturning Ig denials, followed by some additional helpful information, including a link to sample appeal letters that should be tailored to the patient’s clinical history:

  • The appeal should be short, succinct and carefully documented.
  • Keep in mind that you have two minutes of the Medical Director’s attention.
  • Provide well-accepted diagnostic studies which are in the practice guidelines.
  • Provide standards of practical criteria to support the laboratory studies.
  • Provider proof and documentation of serious infections/complications which have not been responsive to appropriate medical/surgical intervention; including clear radiographic evidence of persistent disease, e.g. lungs, sinuses et al, clinical documentation of infections, etc.
  • Focus on the rationale for immunoglobulin therapy – a doctor’s letter that states “because it is medically necessary” is not specific enough to be added to an appeal letter. Precise statements are required, for example, 3 episodes of pneumonia with fever to 102. Chest x-ray (if available) showed lobar pneumonia and xx days of antibiotics were required.
  • Keep in mind that the insurance companies are reviewing thousands of appeals; therefore, the larger packets, will be put to the side. The shorter the appeal, the shorter the turn-around-time for a response.
  • When concluding the letter add the names of the immunologists that have completed the scientific research on the diagnosis in question, should the insurer request a peer review. For example, “Should you have any questions, I would request a peer review by either Dr. John Smith or Dr. Ann Jones from the University School of Medicine.”

For additional information:

The AAAAI IVIG toolkit includes:

The AAAAI IVIG Toolkit has been approved by the AAAAI Board of Directors, and endorsed by the Clinical Immunology Society (CIS) and the Immune Deficiency Foundation (IDF).